This stochastic network modelling study evaluated the population impact and dose efficiency of a partially cross-protective hypothetical vaccine (45% effectiveness) against Bundibugyo virus (BDBV) during a 2026 DR Congo outbreak, comparing base operations, enhanced case-finding/tracing, reactive ring vaccination (Ring 1 & 2), and community vaccination at 20–80% coverage over 90 days.
Enhanced operations alone (70% detection, 80% tracing) reduced expected mortality by 81.6% (95% UI 73.1–87.7%). Adding Ring 2 vaccination to enhanced operations gave only an incremental 10.5% (6.2–15.6%) further mortality reduction; community vaccination at 80% coverage reduced mortality by 86.6% (79.2–90.4%) but required 53.8–111.4 doses per death averted, vs. 35.1 doses per death averted for Ring 2.
The vaccine effectiveness of 45% is hypothetical — no licensed BDBV-specific vaccine exists and true cross-protection from rVSV-ZEBOV is unproven. The model is calibrated to one ongoing outbreak and results may not generalize to other BDBV settings or outbreak sizes. Operational constraints (e.g., cold chain, community acceptance) are approximated rather than empirically validated.
Prioritize rapid case detection, isolation, and contact tracing first — these alone can avert most BDBV deaths even with a partially effective vaccine. If a cross-protective vaccine becomes available, ring vaccination is dose-efficient, but broad community vaccination will be needed to achieve the largest outbreak impact.
Explore related topics